公开(公告)号：US20240109974A1

公开(公告)日：2024-04-04

申请号：US18274845

申请日：2022-01-27

申请人： (JIANGSU SIMCERE PHARMACEUTICAL CO., LTD.)

发明人： Xiaofeng ZHAO ,  Shiqiang LU ,  Zhuoxiao CAO ,  Renhong TANG ,  Jinsheng REN

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C12N15/63

CPC分类号： C07K16/2878 ,  A61K39/4631 ,  A61P35/00 ,  C12N15/63 ,  A61K2239/13 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92

摘要： Disclosed in the present invention are a humanized antibody that can specifically bind to TNFR2, or an antigen-binding fragment thereof. The humanized antibody or antigen-binding fragment thereof can regulate the function of immune cells and can be used in a drug for treating diseases related to immune abnormalities, such as tumours.

公开(公告)号：US20230192797A1

公开(公告)日：2023-06-22

申请号：US17925547

申请日：2021-05-17

申请人： Jiangsu Simcere Pharmaceutical Co., Ltd.

发明人： Jing DENG ,  Shiqiang LU ,  Yang LIU ,  Zhuoxiao CAO ,  Renhong TANG ,  Jinsheng REN

IPC分类号： C07K14/54 ,  C07K16/28 ,  C07K14/715 ,  A61K38/20 ,  A61K45/06 ,  A61P35/00 ,  A61P17/00

CPC分类号： C07K14/5443 ,  C07K16/2827 ,  C07K14/7155 ,  A61K38/2086 ,  A61K45/06 ,  A61P35/00 ,  A61P17/00 ,  C07K2317/92 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2317/24 ,  A61K2039/505

摘要： Provided are a human IL-15 molecule mutant and a fusion protein containing the IL-15 mutant and combined mutations, wherein the fusion protein can mediate the activation and amplification of immune cells and can be used for treating tumor disease

公开(公告)号：US20230002492A1

公开(公告)日：2023-01-05

申请号：US17755741

申请日：2020-11-05

申请人： SIMCERE (SHANGHAI) PHARMACEUTICAL CO., LTD. ,  JIANGSU SIMCERE PHARMACEUTICAL CO., LTD

发明人： Xinyan ZHAO ,  Jing DENG ,  Shiqiang LU ,  Xinxin LI ,  Jinsheng REN

IPC分类号： C07K16/28 ,  A61P35/00

摘要： An antibody or antigen-binding fragment specifically binds to human programmed cell death ligand-1 (PD-L1). The antibody or antigen-binding fragment is able to enhance the function of T cells and upregulate a T cell-mediated immune response. The antibody or the antigen-binding fragment is useful for the treatment of diseases, e.g. tumor, associated with aberrant expression of PD-L1 and/or dysfunction of T cells.

公开(公告)号：US20220017630A1

公开(公告)日：2022-01-20

申请号：US17295773

申请日：2020-07-31

申请人： JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. ,  SIMCERE BIO-PHARMACEUTICAL TECHNOLOGY., LTD.

发明人： Xinyan ZHAO ,  Xiaofeng ZHAO ,  Shiqiang LU ,  Ran PANG ,  Xinxin LI ,  Jinsheng REN

IPC分类号： C07K16/28 ,  G01N33/574 ,  A61P35/00

摘要： An antibody or an antigen-binding fragment thereof capable of specifically binding to TNFR2, the antibody or the antigen-binding fragment thereof is capable of regulating the function of immune cells and may be used as a medicament to treat diseases related to immune-related disorders, such as tumors.